REGENT PACIFIC (00575.HK): Accrua Platform to Launch in US in October

NewTimeSpace News: On 28 September 2026, Regent Pacific Group Limited (stock code: 00575.HK) announced that Deep Longevity, Inc, its wholly owned subsidiary, and its subsidiary will launch Accrua, a consumer digital health and telehealth platform, in the United States in October 2026, and it will be available to consumers across all 50 US states from the date of the launch. The launch represents the culmination of Deep Longevity's strategy of scaling in the US market through a direct-to-consumer (D2C) digital telehealth offering, complementing its existing business-to-business (B2B) model.

At the heart of Accrua is Deep Longevity's proprietary, AI-generated BloodAge report, which uses a routine blood test to indicate whether a consumer is a "faster ager". Following a clinician consultation, Accrua offers doctor-guided access to treatment categories including medications for weight loss (such as GLP-1 therapies), peptides, women's health (such as hormone replacement therapy) and men's health (such as testosterone therapies); the initial treatment plan and subsequent adjustments are personalised by a licensed clinician and anchored to the user's BloodAge report, which is re-measured quarterly.

The announcement stated that the BloodAge model was the subject of a peer-reviewed study by Goshen et al. (Aging and Disease, 2026), which followed approximately 2,600 adults over an average of 9.2 years and found that each additional year of gap between biological and chronological age was independently associated with a 15% increase in mortality risk and a 6% increase in hospitalisation risk, after adjusting for age, sex, body mass index, smoking and hypertension. The technology was named Runner-Up in the Nestlé VITAL Smart Aging Global Challenge, which drew entries from 150 companies worldwide.

Clinical delivery will be provided through established US telehealth infrastructure partners covering all 50 US states, which allows Deep Longevity to scale nationally without owning clinical infrastructure or carrying drug inventory directly, and revenues are expected to be largely subscription-based. The Company stated that Accrua is a newly launched business and the revenues to be generated from it are uncertain, and the development is not expected to have any material impact on the Group's financial position or operating results for the financial year ending 31 December 2026.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.